Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy

Pharmacotherapy

Volumn 30, Issue 5, 2010, Pages 442-452

  Kalyan, Shirin ^a   Hitchcock, Christine L ^a   Sirrs, Sandra ^a   Pudek, Morris ^a   Prior, Jerilynn C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Albumin; Body composition; C reactive protein; CEE; Conjugated equine estrogen; CRP; Inflammation; Lipids; Medroxyprogesterone acetate; MPA; Ovariectomy

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CONJUGATED ESTROGEN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; MEDROXYPROGESTERONE ACETATE; PRASTERONE SULFATE; SERUM ALBUMIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; BODY MASS; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; METABOLIC REGULATION; OVARIECTOMY; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

ADIPOSE TISSUE; ADULT; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYPERTENSION; HYSTERECTOMY; INFLAMMATION MEDIATORS; LIPIDS; LIPOPROTEINS; MEDROXYPROGESTERONE ACETATE; METABOLIC SYNDROME X; MIDDLE AGED; OVARIECTOMY; PROGESTINS; RISK FACTORS; SERUM ALBUMIN;

EID: 77951703236     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.5.442     Document Type: Article

References (52)

1. Gallicchio L, Whiteman MK, Tomic D, et al. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 2006;85:1432-1440
2. Sullivan JM, Vander ZR, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-2562
3. Munoz J, Derstine A, Gower BA. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement. Obes Res 2002;10:424-431 (Pubitemid 135686633)
4. Prentice RL, Anderson GL. The women's health initiative: lessons learned. Annu Rev Public Health 2008;29:131-150
5. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944 (Pubitemid 35283842)
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-534
7. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the women's health initiative. Circulation 2006;113:2425-2434
8. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-780
9. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998;279:1477-1482
10. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100:713-716 (Pubitemid 29383640)
11. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/ Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613
12. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-1439
13. Van Lente F. Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000;293:31-52. (Pubitemid 30103554)
14. Kuhl H, Stevenson J. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits: an attempt to interpret the women's health initiative results. Gynecol Endocrinol 2006;22:303-317
15. Prior JC, Nielsen JD, Hitchcock CL, et al. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. Clin Sci (Lond) 2007;112:517-525
16. Prior JC, Vigna YM, Wark JD, et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12:1851-1863
17. Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982;97:699-705. (Pubitemid 13251641)
18. Haarbo J, Gotfredsen A, Hassager C, Christiansen C. Validation of body-composition by dual energy x-ray absorptiometry (DEXA). Clin Physiol 1991;11:331-341
19. Blight LF, Judd SJ, White GH. Relative diagnostic value of serum non-HBG-bound testosterone, free androgen index and free testosterone in the assessment of mild to moderate hirsutism. Ann Clin Biochem 1989;26(pt 4):311-316
20. Miller KK, Rosner W, Lee H, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab 2004;89:525-533
21. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow-up measurements. BMJ 2001;323:1123-1124
22. Vickers AJ. Parametric versus non-parametric statistics in the analysis of randomized trials with non-normally distributed data [online exclusive article]. BMC Med Res Methodol 2005;5:35. Available from http://www. biomedcentral.com/ 1471-2288/5/35.
23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342: 836-843
24. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
25. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107:391-397
26. Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 1999;100:717-722 (Pubitemid 29383641)
27. Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 1999;100: 713-716 (Pubitemid 29383640)
28. Tibbetts TA, Conneely OM, O'Malley BW. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Biol Reprod 1999;60:1158-1165
29. Cuchacovich M, Tchernitchin A, Gatica H, et al. Intraarticular progesterone: effects of a local treatment for rheumatoid arthritis. J Rheumatol 1988;15:561-565
30. Szekeres-Bartho J, Varga P, Kinsky R, Chaouat G. Progesterone-mediated immunosuppression and the maintenance of pregnancy. Res Immunol 1990;141:175-181
31. Rossi R, Bursi F, Veronesi B, Cagnacci A, Modena MG. Effects of progestins on estrogen-induced increase in C-reactive protein in postmenopausal women. Maturitas 2004;49:315-320 (Pubitemid 39505185)
32. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on vascular inflammatory markers in postmenopausal women receiving estrogen. Circulation 2002;105:1436-1439
33. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135
34. Heilbronn LK, Noakes M, Clifton PM. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Arterioscler Thromb Vasc Biol 2001;21:968-970 (Pubitemid 34168654)
35. Barinas-Mitchell E, Cushman M, Meilahn EN, Tracy RP, Kuller LH. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women. Am J Epidemiol 2001;153: 1094-1101
36. Lear SA, Chen MM, Birmingham CL, Frohlich JJ. The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences. Metabolism 2003;52:1542-1546 (Pubitemid 38049268)
37. Arsenault BJ, Earnest CP, Despres JP, Blair SN, Church TS. Obesity, coffee consumption and CRP levels in postmenopausal overweight/obese women: importance of hormone replacement therapy use. Eur J Clin Nutr 2009;63:1419-1424
38. Moran LJ, Noakes M, Clifton PM, et al. C-reactive protein before and after weight loss in overweight women with and without polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2944-2951
39. Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 2009;204:509-514
40. Vigen C, Hodis HN, Chandler WL, Lobo RA, Mack WJ. Postmenopausal oral estrogen therapy affects hemostatic factors, but does not account for reduction in the progression of subclinical atherosclerosis. J Thromb Haemost 2007;5: 1201-1208
41. Gambacciani M, Ciaponi M, Cappagli B, et al. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. J Clin Endocrinol Metab 1997;82:414-417
42. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study - a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9. (Pubitemid 36232088)
43. Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the women's health initiative hormone trial. Diabetologia 2004;47:1175-1187
44. Bonds DE, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the women's health initiative randomised trial. Diabetologia 2006;49:459-468
45. Sites CK, L'Hommedieu GD, Toth MJ, et al. The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2005;90:2701-2707
46. Ryan AS, Nicklas BJ, Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 2002;25:127-133
47. Torrens JI, Sutton-Tyrrell K, Zhao X, et al. Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of women's health across the nation. Menopause 2009;16:257-264
48. Sutton-Tyrrell K, Wildman RP, Matthews KA, et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the study of women across the nation (SWAN). Circulation 2005;111: 1242-1249
49. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204
50. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001;75:898-915.
51. Ishikawa S, Kayaba K, Gotoh T, et al. Comparison of C-reactive protein levels between serum and plasma samples on long-term frozen storage after a 13.8 year interval: the JMS cohort study. J Epidemiol 2007;17:120-124
52. Aziz N, Fahey JL, Detels R, Butch AW. Analytical performance of a highly sensitive C-reactive protein-based immunoassay and the effects of laboratory variables on levels of protein in blood. Clin Diagn Lab Immunol 2003;10:652-657 (Pubitemid 36890452)